Dense, granular immunoglobulin deposits have been identified at the epidermo-dermal junction in 4 out of 10 patients who developed toxic reactions to D-penicillamine therapy for rheumatoid arthritis. Three of 4 patients developing a lupus-like syndrome while on penicillamine had similar findings on skin biopsy. Serum immunoglobulin and complement levels decreased significantly in patients treat...

Penicillamine (P,fl-dimethylcysteine) is a degradation product of all the known naturally occurring penicillins (1). It was first reported in 1943 (2). Since that time most investigations have dealt with its preparation, chemical properties, or relationship to penicillin, and little information is available regarding its biological behavior. The purpose of the present paper is to report the res...

Thirty-eight patients with rheumatoid arthritis in remission on penicillamine were entered into a prospective, randomised, placebo controlled study to determine the effects of gradual penicillamine withdrawal, to find a serological marker capable of predicting relapse, and to assess the effects of reintroduction of penicillamine. 80% of patients attempting gradual penicillamine withdrawal flare...

Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients. Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear. We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy. We...

BACKGROUND Penicillamine, once considered the cornerstone of treatment for Wilson disease (WD), is rather expensive and toxic, and often causes neurological worsening. Zinc sulphate, aiming at the treatment of free-copper toxicosis, has emerged as effective, safe and cheap alternative. AIM To assess the effect of withdrawal of penicillamine from maintenance treatment with penicillamine and zi...

A patient with sero-positive rheumatoid arthritis was treated with D-penicillamine (cumulative dose 3 . 7 3 9 . Three weeks after starting therapy she developed a fever, rash and a cholestatic jaundice. Cessation of D-penicillamine resulted in improvement. However, reintroduction of D-penicillamine 1 0 days later (cumulative dose 2g), was followed by acute hepatic failure and death. Liver biops...

Penicillamine toxicity in Wilson's disease has been well reported but rarely seen now as newer agents are being used. We present a case who developed multiple rare complications of Penicillamine concurrently. Our patient is one of three siblings on Penicillamine, she was the only one who developed massive breast enlargement four months after commencing Penicillamine therapy, as well as dermatol...

Ishihara, N., Shiojima, S., and Suzuki, T. (1974). British Journal of Industrial Medicine, 31, 245-249. Selective enhancement of urinary organic mercury excretion by D-penicillamine. This report deals with the study of a patient who was suspected of having mercury vapour poisoning and was treated with D-penicillamine. D-penicillamine by mouth enhanced the urinary excretion of organic but not in...

First, an effective pre-concentration of penicillamine was done via Fe3O4NPS. Then, a simple, rapid and sensitive spectrophotometric method is described for the determination of penicillamine by 2, 6-dichlorophenolindophenol (2, 6-DCPIP), as the chromogenic agent in bulk drug and formulations. It produces a bluish green coloured compound with maximum absorbance 610 nm. Bee...